ADMA Biologics (NASDAQ:ADMA) Raised to "Hold" at StockNews.com
StockNews.com upgraded shares of ADMA Biologics (NASDAQ:ADMA – Free Report) from a sell rating to a hold rating in a research report report published on Saturday. Other research analysts also recently issued research reports about the stock. Mizuho lifted their price target on shares of ADMA Biologics from $6.00 to $7.00 in a research note […]